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Accepted 5 January 2011AbstractObjective: To present intensive intrauterine treatment of recurrent early onset fetal erythroblastosis due to anti-M alloimmunization.
Case Report: A 33-year-old woman, gravid 3, para 1, had anti-M IgG antibody, which caused alloimmunization of her previous pregnancies.
This time she visited our hospital for intensive intervention. No evidence of fetal hydrops was found during ultrasound examination at 12 weeks
of gestation. Plasmapheresis was given from 17 weeks of gestation but fetal erythroblastosis still developed 1 week later. Two intraperitoneal
transfusions and one intracardiac transfusion were given within three days but fetal erythroblastosis still progressed to fetal bradycardia and
occasional asystole. Epinephrine resuscitation could only temporarily improve the fetal heart rate and fetal death was inevitable.
Conclusion: Serial measurements of fetal middle cerebral artery peak systolic velocities, advanced plasmapheresis, intrauterine blood trans-
fusion, and, if needed, intravenous immunoglobulin supplement, may be the appropriate treatment for early onset fetal erythroblastosis resulting
from alloimmunization.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Most cases of fetal erythroblastosis are caused by Rhesus
alloimmunization, which was firstly reported by Levine et al in
1941 [1]. Maternal prophylaxis with RhoGAM successfully
decreases the incidence of erythroblastosis fetalis. However,
there are still some other blood-type incompatibilities, such as
Kell, Duffy, Kidd, and the MNS system, that may be the cause
of fetal erythroblastosis but are without treatment consensus.
Antibodies with anti-M specificity, usually IgM, have been
reported to be detected in 10% of pregnant women with
a positive antibody screen. However, 0.01% to 0.7% of preg-
nant women would trigger anti-M IgG that can cross the* Corresponding author. 8 Zhongshan South Road, Zhongzheng District,
Taipei City, Taiwan.
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doi:10.1016/j.tjog.2012.04.013placenta, resulting in variable degrees of hemolysis in fetuses
[2,3]. Only sporadic cases of anti-M isoimmunization have
been reported during past few decades. We report a case of
recurrent early-onset fetal erythroblastosis due to anti-M
alloimmunization that was treated with fetal intraperitoneal
and intracardiac transfusion but still resulted in intrauterine
fetal death.
Case report
The patient was a 33-year-old female. Her first male baby
was born at 40 weeks gestational age complicated with car-
diomegaly and congenital hemolytic disease of the newborn
and who became healthy after blood transfusion 3 years before
this admission. Serological tests of congenital infection
including pavovirus B19, toxoplasma, cytomegalovirus,
rubella, and herpes simplex were all negative. An irregular
anti-M antibody (IgG) was identified by antibody screeningcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. Ultrasound picture at gestational age 19 weeks, showing fetal gener-
alized skin edema, pericardial effusion, pleural effusion, and massive ascites.
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test revealed evidence of fetalematernal hemorrhage. Thus,
the subsequent hemodynamic changes of the newborn were
caused by anti-M alloimmunization. Plasmapheresis and
intravascular transfusion via cordocentesis were planned for
the patient’s second pregnancy. However, the pregnancy ended
in unexpected early-onset hydrops with intrauterine fetal death
at gestational age 18 weeks 1 year before this admission.
This third pregnancy received combined care by obstetric
and hematologic physicians. The treatment plan was thor-
oughly explained to the patient and her family. The first
trimester nuchal translucency examination at gestational age
12 weeks did not disclose any hydropic sign (Fig. 1). Plas-
mapheresis starting from 17 weeks’ gestation was advised by
hematologic physicians, with the frequency depending on the
level of antibody titer. The anti-M IgG antibody titer
decreased from 1:32 to 1:8 thereafter. However, hydrops
fetalis developed 1 week later. Gestational age prior to 20
weeks made it difficult to gain fetal intravascular access for
transfusion. A 20-gauge needle was placed into the fetal
hydropic abdominal cavity for slowly transfusion of 5 mL
donor blood under direct ultrasound guidance with informed
consent. Care was taken to avoid the liver and the kidneys.
Three days later, at gestational age 19 weeks and 2 days, the
hydrops fetalis progressed to generalized skin edema, peri-
cardial effusion, pleural effusion, and massive ascites (Fig. 2).
Fetal heart rate decreased to 100 beats/minute. Fetal blood
was obtained by cordocentesis. The fetal hemoglobin
concentration and hematocrit were 1.1 g/dL and 3.2%,
respectively, indicating severe anemia. Attempts to perform an
intravascular transfusion were unsuccessful. Afterwards,
intrauterine intraperitoneal/intracardiac transfusion of 7 mL
and 17 mL donor blood were given urgently. Intravenous
immunoglobulin (1 g/kg/day) was also given. Persistent fetal
bradycardia and occasional asystole were temporarily
improved after serial intracardiac 0.1 mL epinephrine
(1:10,000) resuscitation; however, intrauterine fetal death 3
hours later was inevitable.Fig. 1. Ultrasound picture for measurement of nuchal translucency at gesta-
tional age 12 weeks. There was no evidence of fetal erythroblastosis at this
time.Discussion
Antigen M incompatibility between mother and fetus is an
extremely rare cause of red-cell alloimmunization. Consid-
ering the low frequency of anti-M alloimmunization, routine
prenatal screening of anti-M antibody is unnecessary.
Fetal surveillance using either middle cerebral artery peak
systolic velocity measurements or fetal hemoglobin results
obtained by fetal blood sampling is important for management
of alloimmunized pregnancies. Intravascular routes, superi-
ority to intraperitoneal route for blood transfusion has been
demonstrated in a previous case-controlled study [4], but the
route of treatment prior to 20 weeks’ gestation is limited by
technical aspects. Hence early-onset fetal hemolytic disease
continues to be a challenging clinical entity.
Von Kaisenberg et al treated a hydropic monochrionic twin
by both intraperitoneal and intracardiac transfusions [5],
However, Lewis et al reported that hydropic fetuses were
unable to absorb red cells from their peritoneal cavity [6]. To
overcome this, early intraperitoneal transfusion before there is
evidence of erythroblastosis fetalis should be a better way for
treatment of early-onset isoimmunized pregnancies. David
et al reported five cases experience of serial intraperitoneal
transfusion starting before the onset of hydrops and continuing
until 20 to 22 weeks of gestation and all of them had favorable
prognosis [7].
An alternative route to the fetal intravascular space is by
direct puncture of the fetal heart, but this is potentially
dangerous. Six patients with pregnancies of 19 to 31 weeks’
duration displaying evidence of erythroblastosis fetalis were
treated with a total of 25 times with fetal intracardiac blood
transfusions. The live birth rate was 66.7% [8]. Complications
included bradycardia, asystole, and hemopericardium.
However, the fetal cardiac structure cannot be clearly identi-
fied before 18 weeks of gestation. We cannot convince
ourselves to use a potentially high-risk procedure to treat the
fetus before hydrops develop. Intracardiac transfusion should
be preserved as a second-line treatment of choice.
Van Kamp et al illustrated an overall intrauterine therapy
procedure-related fetal loss rate of 5.6% [9]. It should be higher
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a reason to search for a noninvasive treatment for the fetus in
these circumstances. Most experiences and reports are from
treatment of patientswithRh alloimmunization. Plasmapheresis
aims to decrease the target antibody titer by direct plasma
replacement. Intravenous immunoglobulin (IVIG) blocks the Fc
receptors of the fetal reticulo-endothelial system, thereby
reducing the degree of phagocytosis of sensitized fetal red cells.
Both plasmapheresis and IVIG have been utilized individually
for their effect of prolongation of gestation prior to the need for
intrauterine therapy. Combined plasmapheresis and IVIG
therapy has also been utilized in a variety of antibody-mediated
diseases. Only 16 patients have been reported in the literature
using combined treatment in maternal red cell alloimmuniza-
tion, and all had favorable outcome [10e12]. The dosage of
IVIG is 1 g/kg, and administration interval ranged from 3 times/
week to every 20 days according to the patients’ antibody titer.
The cost of IVIG is extremely expensive, and cost-benefit effi-
ciency requires a further larger study evaluation.
In summary, anti-M alloimmunization was the cause of our
case’s fetal hemolytic anemia and intrauterine fetal death.
Although the highest anti-M IgG titer was only 1:32, the fetal
erythroblastosis still appeared too rapidly and we were caught
unawares. Based on the previous reports and literature
reviews, combined treatment of plasmapheresis, IVIG, and
intrauterine blood transfusion may have been appropriate for
our patient. Plasmapheresis may start as soon as possible right
after pregnancy is confirmed to lower the anti-M IgG titer.
Serial ultrasonograhic examinations every 1 to 2 weeks and
measured middle cerebral artery Doppler peak systolic
velocities can provide us more information about fetal
hemodynamic status. Treatment should be given before the
onset of hydrops with serial intraperitoneal transfusion and
continuing until 20 to 22 weeks of gestation when intravas-
cular transfusion is feasible. IVIG can also provide an addi-
tional protection, but the cost-benefit efficiency should be
discussed with the patient and her family. Intracardiac bloodtransfusion may be associated with potentially severe
complications and should be reserved until previous methods
failure.
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